Continue to meet or exceed healthcare partners’ expectations by providing on-time test results approximately 92 percent of the time.
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...